Table 2 Evolution of the laboratory values after stopping imatinib or nilotinib

From: Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

At baseline

At 6 months after discontinuation

 

Imatinib

Nilotinib

P

Imatinib

Nilotinib

P

Hb, g/dLa

12.5 (11.7–13.7)

13.5 (12.5–14.8)

0.002

13.5 (12.7–14.3)

13.6 (12.4–14.8)

0.74

Leukocytes, × 109/La

5.4 (4.5.6.9)

7.8 (6.1–9.1)

<0.001

6.5 (5.4–8)

7.25 (6.1–9.1)

0.11

Lymphocytes, × 109/La

1.8 (1.5–2.3)

2 (1.6–2.4)

0.063

2.1 (1.75–2.6)

1.85 (1.6–2.5)

0.18

Platelets, × 109/La

215 (190–257)

223 (180–269)

0.59

255 (205–286)

214 (181–271)

0.09

Creatinine, mg/dLa

0.97 (0.8–1.17)

0.86 (0.72–1.05)

0.025

0.9 (0.73–1.08)

0.89 (0.72–1.05)

0.67

Total cholesterol, mg/dLa

181 (155–203)

206 (160–238)

0.025

207 (178–232)

172 (140–210)

0.004

  1. aMedian (interquartile range)
  2. The Mann–Whitney U-test was used for comparisons
  3. Numbers in bold are those with a significant P-value on the statistical analysis (P < 0.05)